Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Rev Neurol. 2013 Feb;9(2):72-3. doi: 10.1038/nrneurol.2012.277. Epub 2013 Jan 22.

Multiple sclerosis in 2012: Novel therapeutic options and drug targets in MS.

Author information

1
Focus Program Translational Neuroscience, Rhine Main Neuroscience Network, Johannes Gutenberg University Medical Centre Mainz, Department of Neurology, Langenbeckstrasse 1, D-55131 Mainz, Germany. axel.methner@unimedizin-mainz.de

Erratum in

  • Nat Rev Neurol. 2013 May;9(5):240.

Abstract

2012 witnessed important developments for multiple sclerosis, including successful phase III trials of novel oral therapeutics and identification of the potassium channel KIR4.1 as an autoimmune target. Additionally, the lung was highlighted as an important site for immune-cell programming, and the relevance of a TNF receptor variant was clarified.

PMID:
23338282
DOI:
10.1038/nrneurol.2012.277
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Support Center